A UK High Court ruled on Monday that a ban on the prescription and sale of puberty blockers for individuals under the age of 18 experiencing gender dysphoria is lawful. This decision comes following a legal challenge by TransAction, an advocacy organisation for transgender healthcare and legal protections, and an anonymous transgender young person. They claimed the ban was enacted unlawfully by the Secretary of State for Health and Social Care.
According to the judgment, the claim failed on all three grounds. The court found that the emergency procedures used to implement the ban were justified due to scientific uncertainty, thus validating the Health Secretary’s decision. Additionally, the court ruled there was no legal obligation to consult organisations working with transgender individuals before implementing the ban. Even if such consultations had been conducted, the court deemed it unlikely that they would have influenced the legislation. Lastly, the court dismissed the argument that the ban breached the Article 8 rights of the young transgender individual involved in the case.
The ban, introduced on May 29, 2024, by the previous Conservative government, restricts the use of puberty blockers for those under 18 in the UK. The Health Secretary defended the policy, citing it was necessary to protect vulnerable children from medical pathways with significant risks and no clear benefits.
TransAction criticised the court’s ruling, particularly the reliance on the “Cass Review,” which the Health Secretary used as scientific evidence supporting the restriction of puberty blockers. The review, conducted by Dr. Hilary Cass, advocates for the use of puberty blockers only under a research protocol. Critics, including the Yale School of Medicine, argue that the review excludes trans researchers and includes anti-trans academics.
Chay Brown, Director for Healthcare at TransAction, expressed concerns over the ruling, stating it endangers the safety and welfare of young transgender individuals in the UK. TransAction has urged NHS England and the Department of Health and Social Care to take steps to rebuild trust with the transgender community and is considering an appeal against the decision.
For further details, please refer to the original article.